Clin Cancer Res: Efficacy, safety and biomarkers of torepalizumab in second-line treatment of metastatic urothelial cancer

Immunotherapy provides a second-line option for patients with metastatic urothelial carcinoma (mUC) who have failed standard treatment, but biomarkers that predict the response of mUC patients to immunotherapy remain to be explored

This study aims to evaluate the safety, efficacy and related biomarkers of toripalimab in mUC patients who have previously received treatment

The recruited mUC patients received torepalizumab 3 mg/kg Q2W treatment

Overall survival rate of the intention-to-treat population

In the intention-to-treat population (n=151)

Progression-free survival rate of PD-L1 positive or negative patients

The objective response rate of patients with PD-L1 positive and high TMB value (≥10 mutations/Mb) was significantly higher than that of PD-L1 negative patients (42% vs 17%; p=0.

Progression-free productivity in patients with high and low TMB values

All in all, the results of the study show that torepalizumab as a second-line therapy for patients with metastatic urothelial cancer who failed the first-line treatment has shown encouraging clinical activity and controllable safety

Original source:

Sheng Xinan,Chen Haige,Hu Bin et al.